Its first product, EndeavorRx was developed by Adam Gazzaley, Professor of Neurology, Physiology, and Psychiatry at the University of California, San Francisco, to help improve attention in children between the ages of 8 and 12 with attention deficit hyperactivity disorder, or ADHD. Following it down the pipeline are programs to treat a broader range of kids with ADHD, as well as new games to address the symptoms of autism spectrum disorder, post-COVID-19 “brain fog” and multiple sclerosis. Akili Interactive is now turning its attention to other neurological conditions that its particular brand of video game-based treatments could potentially address.
